- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05349955
Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community (GUARD)
Effects and Safety of GUideline Algorithm Based Intervention on CaRdiovascular and Renal Outcomes in Elderly Diabetic Patients With High Cardiovascular Risk in the Community- A Cluster Randomized Controlled Trial (GUARD-Community Study)
Study Overview
Status
Detailed Description
Diabetes is an important public health concern. Elderly diabetic patients are characterized by a long duration and complications, including chronic kidney disease and/or cardiovascular disease. In the past 30 years, the guidelines of CDS, EASD or ADA have been frequently updated. The latest guideline on pharmacological algorithm recommend that patients with cardiovascular, renal disease or very high/high CV risk patients should be treated with anti-diabetic drugs presenting target organ protection, including SGLT2i and GLP1RA. And the guideline recommend comprehensive control of the cardiovascular risk factors, such as hypertension and dyslipidemia.
This GUARD-Community study is a community based cluster-randomized controlled trial and will enroll 5600 or more participants in more than 120 clusters aged ≥ 65 years with T2DM and complicated with high/very high cardiovascular risk factors . The trial will evaluate the the effects and safety of intensive "Guideline" algorithm implementation on CVD and renal outcomes. The primary hypothesis is that guideline algorithm intervention implemented by primary care physicians will significantly reduce the risk of 4-point MACE (comprised of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization of heart failure) rates. In Phase 1 study, the control of blood sugar, blood pressure and lipids will be evaluated at 18 months after intervention. In Phase 2 study, the CVD and renal outcomes will be evaluated at 3 years. The study will last for 4 years.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xiaomu Li, MD
- Phone Number: 13661676591
- Email: li.xiaomu@zs-hospital.sh.cn
Study Contact Backup
- Name: Xiaoying Li, MD
- Phone Number: 13651913857
- Email: li.xiaoying@zs-hospital.sh.cn
Study Locations
-
-
Jaingsu
-
Suzhou, Jaingsu, China, 215501
- Recruiting
- Xiangcheng Second People's Hospital
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Not yet recruiting
- Caohu Community Healthcare Center
-
Suzhou, Jiangsu, China, 215131
- Recruiting
- Xiangcheng People's Hospital.
-
Contact:
- Xuefei Xu, Bachelor
- Phone Number: 18818211531
- Email: pyu15@fudan.edu.cn
-
Suzhou, Jiangsu, China, 215137
- Recruiting
- Taiping Community Healthcare Center
-
Contact:
- Xuejian Ni, Bachelor
- Email: 2314831056@qq.com
-
Suzhou, Jiangsu, China, 215138
- Not yet recruiting
- Yangchenghu People's Hospital
-
Suzhou, Jiangsu, China, 215141
- Not yet recruiting
- Health Center of Xiangcheng Tourism Resort
-
Suzhou, Jiangsu, China, 215131
- Recruiting
- Yuanhe Community Healthcare Center
-
Suzhou, Jiangsu, China, 215152
- Recruiting
- Dongqiao Community Healthcare Center
-
Suzhou, Jiangsu, China, 215134
- Recruiting
- Xiangcheng Third People's Hospital
-
Suzhou, Jiangsu, China, 215155
- Recruiting
- Xiangcheng Traditional Chinese Medicine Hospital
-
Contact:
- Jichao Yu, Bachelor
- Email: 344314300@qq.com
-
Suzhou, Jiangsu, China, 215006
- Recruiting
- Huangqiao Community Healthcare Center
-
Suzhou, Jiangsu, China, 215144
- Recruiting
- Caohu People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ①Males or females aged 65 and above (≥65) receive treatment from the local community health service center;
- ②Diagnosed type 2 diabetes (ADA criteria):
- A. Typical symptoms of diabetes + random blood sugar ≥ 11.1mmol/L;
- B. Fasting blood glucose (FPG) ≥ 7.0mmol/L (fasting blood glucose is defined as no caloric intake within 8 hours);
- C. Oral glucose tolerance test 2h blood glucose (OGTT) ≥ 11.1mmol/L (2h after meal);
- D. have been treated with antidiabetic drugs;
- Each blood sugar test must be repeated to confirm the diagnosis;
- ③Complicated with chronic kidney disease and/or very high/high risk of cardiovascular disease, meet any one of the following:
- A. ASCVD, including coronary heart disease, cerebral infarction, peripheral vascular disease;
- B. Or target organ damage (albuminuria, renal impairment with eGFR ≥ 30 ml/min/1.73m2, left ventricular hypertrophy or retinopathy);
- C. ≥ 3 major risk factors (age ≥ 65 years old, hypertension, dyslipidemia, smoking, obesity );
- D. Diabetes duration ≥ 10 years, with any one traditional cardiovascular risk factor such as advanced age, obesity, smoking, sedentary, family history of cardiovascular disease, hypertension, abnormal lipid metabolism.
Exclusion Criteria:
- ①Pregnant women or women planning to become pregnant;
- ②eGFR<30 mL/min/1.73m2 (CKD-EPI formula);
- ③Patient cannot be followed up for 36 months (due to health condition or migration);
- ④Unwilling or unable to sign the informed consent;
- ⑤Type 1 diabetes;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intensive guideline algorithm implementation
SGLT2i or GLP-1RA recommended in priority in subjects at very high/high CV risk.
The targets of intervention will be achieved at HbA1C <7%, blood pressure <130/80mmHg, LDL-c<1.8mmol/L at very high CV risk or <2.6mmol/L at high CV risk patients, antiplatelet as secondary prevention of ASCVD.
|
Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community.
In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C<7%, control blood pressure <130/80mmHg, LDL-c<1.8mmol/L at very high CV risk patients or <2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
|
Active Comparator: Conventional guideline algorithm implementation
Treatment based on the current approaches implemented by local physicians(primary care physicians).
Guideline based education and consults will be conducted to primary care physicians.
|
The guideline intervention is based the guidance which the local physicians followed through self learning and education.
The management of diabetes paitients will be decided by local physicians.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Outcome of Phase 1: Comprehensive management effect of various cardiovascular risk factors in T2D,meeting control targets for a combination of A1c, BP, LDL-C.
Time Frame: 18 months since randomization
|
The proportion of participants with HbA1C<7.0%,
blood pressure< 130/80 mm Hg,LDL-c<1.8mmol/L at very high CV risk or <2.6mmol/L at high CV risk.
|
18 months since randomization
|
Primary Outcome of Phase 2: Composite of 3P MACE and hospitalization for heart failure.
Time Frame: 3 years since randomization
|
Time to occurrence of cardiovascular and cerebrovascular death, non-fatal myocardial infarction, non-fatal Stroke, hospitalization for heart failure.
|
3 years since randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Outcome of Phase 1: Glycemic control rate
Time Frame: 18 months since randomization
|
The proportion of participants with tight glucose control, targeting HbA1c <7.0%
|
18 months since randomization
|
Secondary Outcome of Phase 1: Mean HbA1C changes
Time Frame: 18 months since randomization
|
Mean HbA1C changes of participants
|
18 months since randomization
|
Secondary Outcome of Phase 1: Mean systolic and diastolic pressure changes
Time Frame: 18 months since randomization
|
Mean systolic and diastolic pressure changes of participants
|
18 months since randomization
|
Secondary Outcome of Phase 1: Mean LDL-c changes
Time Frame: 18 months since randomization
|
Mean LDL-c changes of participants
|
18 months since randomization
|
Secondary Outcome of Phase 1: Adherence to guideline algorithm medication recommendation rate
Time Frame: 18 months since randomization
|
Use electronic medical recorded prescription and questionnaires to assess the proportion of participants who adhere to guideline recommended medication
|
18 months since randomization
|
Secondary Outcome of Phase 2: Incident or worsening nephropathy
Time Frame: 3 years since randomization
|
Time to composite of incident macroalbuminuria (UACR >300 mg/g), a sustained decline in eGFR (decrease in the eGFR of 30% or more to a value of less than 60 when baseline ≥60ml per minute per 1.73 m2, decrease in the eGFR of 50% or more when baseline <60ml per minute per 1.73 m2)from baseline, or chronic renal replacement therapy, or renal death.
|
3 years since randomization
|
Secondary Outcome of Phase 2: Cardiorenal composite endpoint
Time Frame: 3 years since randomization
|
Time to eGFR (CKD-EPI formula) decrease, renal replacement therapy, renal or cardiovascular death
|
3 years since randomization
|
Secondary Outcome of Phase 2: 3P MACE
Time Frame: 3 years since randomization
|
Time to events occurence: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke
|
3 years since randomization
|
Secondary Outcome of Phase 2: New onset of macroalbuminuria.
Time Frame: 3 years since randomization
|
Time to UACR>300mg/g
|
3 years since randomization
|
Secondary Outcome of Phase 2: Changes of myocardial ischemia in electrocardiogram (ECG)
Time Frame: 3 years since randomization
|
Participants number of ECG ischemia demonstration occurence: ST-T segment depression more than 0.1mv in two adjacent leads of ECG compared with baseline, poor R wave progression.
|
3 years since randomization
|
Secondary Outcome of Phase 2: New onset of albuminuria
Time Frame: 3 years since randomization
|
Time to UACR increase from <30mg/g to ≥30mg/g
|
3 years since randomization
|
Secondary Outcome of Phase 2: Albuminuria progression
Time Frame: 3 years since randomization
|
Time to albuminuria progression: UACR increased by ≥30% and grade progression (ie, from normal to micro or macro, or from micro to macro)
|
3 years since randomization
|
Secondary Outcome of Phase 2: Albuminuria regression
Time Frame: 3 years since randomization
|
Time to albuminuria regression: UACR grade regression(ie, from macro to micro or normal, or from micro to normal), and the UACR value decreases by more than or equal to 30%
|
3 years since randomization
|
Secondary Outcome of Phase 2: Changes in the ratio of patients with normal or abnormal urine protein at the end of the study
Time Frame: 3 years since randomization
|
Rate change of normal or abnormal UACR.
Normal means UACR<30mg/g.
Abnormal means UACR≥30mg/g
|
3 years since randomization
|
Secondary Outcome of Phase 2: Slope of eGFR decline
Time Frame: 3 years since randomization
|
Decrease of the eGFR over time
|
3 years since randomization
|
Secondary Outcome of Phase 2: Retinopathy changes
Time Frame: 3 years since randomization
|
Occurrence or regression of retinopathy(ETDRS-DRSS)
|
3 years since randomization
|
Secondary Outcome of Phase 2: Body weight change
Time Frame: 3 years since randomization
|
Absolute weight change and the percentage change of body weight
|
3 years since randomization
|
Secondary Outcome of Phase 2: Changes of fatty liver prevalence
Time Frame: 3 years since randomization
|
Rate change of fatty liver.
|
3 years since randomization
|
Secondary Outcome of Phase 2: Changes in beta-cell function
Time Frame: 3 years since randomization
|
Absolute change assessed by HOMA2-%β method
|
3 years since randomization
|
Secondary Outcome of Phase 2: Changes in cognitive function
Time Frame: 3 years since randomization
|
Improvement or progression of cognitive function: The Mini-CogTM scale
|
3 years since randomization
|
Secondary Outcome of Phase 2: The FRAIL scale
Time Frame: 3 years since randomization
|
Changes of the simple frailty questionnaire score
|
3 years since randomization
|
Secondary Outcome of Phase 2: All-cause death
Time Frame: 3 years since randomization
|
Time to the death due to any cause
|
3 years since randomization
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health Economics Indicators
Time Frame: 3 years since randomization
|
Cost-effectiveness analysis: quantification of Incremental Cost Ratio Life Cycle (ICER) and Quality Adjusted Years (QALYs)
|
3 years since randomization
|
Changes in cardiovascular risk indicators
Time Frame: 3 years since randomization
|
Framingham score
|
3 years since randomization
|
Serology and urine testing
Time Frame: 3 years since randomization
|
Biomarkers associated with diagnosis or prognosis: using "omics" screening.
|
3 years since randomization
|
Genomics testing
Time Frame: 3 years since randomization
|
Gene polymorphism testing for drug response or prognosis: using genome-wide association study(GWAS) screening.
|
3 years since randomization
|
The time rate of glycemic target range
Time Frame: 3 years since randomization
|
Continous glucose monitor detection
|
3 years since randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Xiaoying Li, MD, Fudan University
Publications and helpful links
General Publications
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
- Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum In: Lancet 1999 Aug 14;354(9178):602.
- Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
- Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M, Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486. No abstract available. Erratum In: Eur Heart J. 2020 Dec 1;41(45):4317.
- Gu TW, Zhu DL. [Interpretation of treatment part of national guideline for the prevention and control of diabetes in primary care (2018)]. Zhonghua Nei Ke Za Zhi. 2019 Jul 1;58(7):538-540. doi: 10.3760/cma.j.issn.0578-1426.2019.07.011. Chinese.
- Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005 Jan;28(1):164-76. doi: 10.2337/diacare.28.1.164.
- Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
- Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
- Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
- Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
- American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. doi: 10.2337/dc21-S009.
- Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021 Aug;44(8):1805-1815. doi: 10.2337/dc21-0076. Epub 2021 Jul 7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZSE 20220401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Kidney Disease
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Chinese PLA General HospitalBeijing Friendship Hospital; Guang'anmen Hospital of China Academy of Chinese... and other collaboratorsRecruitingDiabetic Kidney DiseaseChina
-
Omar Tarek ElfarargiNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...Not yet recruitingEstablishment and Clinical Validation of a New Technique for Early Diagnosis of Diabetic NephropathyDiabetes Mellitus | Diabetic Kidney Disease | Biomarkers | Early Diagnosis
-
Fayoum UniversityCairo UniversityNot yet recruitingSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Mayo ClinicRegenerative Medicine MinnesotaTerminatedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetic Kidney Disease | Diabetic Nephropathies | Chronic Kidney Disease | Kidney Failure | Diabetic Nephropathy Type 2 | Kidney InsufficiencyUnited States
-
CSL BehringCompletedDiabetic Kidney Disease (DKD)United States, Australia, New Zealand, Puerto Rico, Canada, Israel
-
Universidad Estatal de MilagroSecretaría de Ciencia, Tecnología e Innovación (Senescyt); PROMETEOUnknownKidney Diseases | Diabetes Mellitus | Diabetic Nephropathy | Diabetic Kidney Disease | Chronic Kidney DiseaseEcuador
-
The First Affiliated Hospital of Xiamen UniversityNot yet recruitingDiabetic Nephropathies
Clinical Trials on Intensive guideline algorithm implementation
-
University of AarhusAalborg UniversityCompleted
-
US Department of Veterans AffairsIowa State University; National Jewish Hospital QuitlineCompletedCigarette SmokingUnited States
-
US Department of Veterans AffairsCompletedSchizophreniaUnited States
-
University of FloridaBrooks Rehabilitation; Foundation for Physical Therapy ResearchCompletedLow Back Pain | Neck PainUnited States
-
University Hospital, GrenobleFondation ApicilCompletedAgitation,PsychomotorFrance
-
Meyer Children's Hospital IRCCSRecruitingChronic Kidney DiseasesItaly
-
PD Dr. Jan KottnerCompletedPruritus | Intertrigo | Skin Care | Pressure Ulcer | Xerosis Cutis | Dry Skin | Incontinence-associated Dermatitis | Skin TearGermany
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)Active, not recruitingMild Traumatic Brain InjuryCanada
-
University of AarhusResearch Unit for General Practice, Aarhus University; Ringkoebing-Skjern Municipality... and other collaboratorsCompletedCOPD | Implementation of a Chronic Disease Management Programme
-
University of IowaNational Institute on Drug Abuse (NIDA)CompletedCigarette SmokingUnited States